Omalizumab for COPD with indoor allergen sensitivity
Clinical trial of omalizumab for allergen sensitized and exposed individuals with COPD
Omalizumab, a medicine that reduces allergic reactions, will be given to adults with COPD who are allergic to and exposed to indoor allergens to see if it lowers flare-ups and complications.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11388988 on NIH RePORTER |
What this research studies
If you join, you would be an adult with COPD who has allergic sensitization and ongoing exposure to common indoor allergens and elevated IgE. Participants are randomly assigned, without knowing which group they are in, to receive either omalizumab injections or a placebo at study visits at participating centers. The study team will track symptoms, lung flare-ups (exacerbations), safety, and blood markers over time and may do allergy and lung function tests. The trial is run at multiple medical centers and is designed to find out whether targeting allergy-related inflammation helps this subgroup of COPD patients.
Who could benefit from this research
Good fit: Adults (21 years and older) with diagnosed COPD who show sensitization to common indoor allergens, have ongoing exposure to those allergens, and have elevated total IgE are the ideal candidates.
Not a fit: People with COPD who are not allergic to or not exposed to indoor allergens, who have low IgE, or who have other COPD subtypes are unlikely to benefit from this treatment approach.
Why it matters
Potential benefit: If successful, this could reduce COPD exacerbations and allergy-related inflammation for people with allergy-sensitized COPD.
How similar studies have performed: Omalizumab is an established treatment for allergic asthma, but testing it specifically in allergy-sensitized COPD is new and based on promising observational signals rather than large prior trials.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Putcha, Nirupama — Johns Hopkins University
- Study coordinator: Putcha, Nirupama
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.